Severe anaphylactic shock is a life-threatening situation that needs immediate treatment of progressive hemodynamic failure. We report two cases of severe anaphylactic shock treated with arginine-vasopressin (AVP): In a 42-year-old male patient anaphylactic shock was caused by the sting of a hornet. At the scene, he was found unconscious, cyanotic, with a heart rate of 130/min without measurable blood pressure. The patient was intubated and ventilated with 100% oxygen, intravenous epinephrine (1 mg over 2 min) had no effect on blood pressure. After injection of 10 IU vasopressin, followed by infusion of 40 IU vasopressin, hemodynamics could be stabilized at once. In the second case, a 47-year-old male patient was stung by a wasp. At the scene he was unconscious, blood pressure was not measurable, heart rate was 140/min. The patient was treated with 40 IU vasopressin followed by rapid infusion of 500 ml NaCl 0.9%. After injection of vasopressin, blood pressure raised to 80/50 mm Hg and heart rate decreased to 90/min. Both patients needed ventilator therapy for several days and recovered fully.

1.
The European Resuscitation Council: Part 8: Advanced challenges in resuscitation. Section 3: Special challenges in ECC. 3D: Anaphylaxis. Resuscitation 2000;46:59–65.
2.
Reimers A, Muller U: Treatment of anaphylactic shock. Ther Umsch 2001;58:325–328.
3.
Bautista E, Simons FER, Simons KJ, Becker AB, Duke K, Tilett M, Kepron W, Mink SN: Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock. Int Arch Allergy Immunol 2002;128:151–164.
4.
Mink SN, Bands C, Becker A, Elkin J, Sharma S, Unruh H, Kepron W: Effect of bolus epinephrine on systemic hemodynamics in canine anaphylactic shock. Cardiovasc Res 1998;40:546–556.
5.
The European Resuscitation Council: Part 6:Advanced cardiovascular life support. Section 6: Pharmacology II: Agents to optimize cardiac output and blood pressure. Resuscitation 2000;46:156–157.
6.
Wenzel V, Lindner KH: Arginine vasopressin during cardiopulmonary resuscitation: Laboratory evidence, clinical experience and recommendations, and a view to the future. Crit Care Med 2002;30(4 suppl):S157–S161.
7.
Tsuda A, Tanaka KA, Huraux C, Szlam F, Sato N, Yamaguchi K, Levy JH: The in vitro reversal of histamine-induced vasodilation in the human internal mammary artery. Anesth Analg 2001;93:1453–1459.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.